The China myasthenia gravis treatment market is expected to witness significant growth owing to rise in prevalence of myasthenia gravis and presence of scientific facilities for its diagnosis and monitoring in the country. Myasthenia gravis is a prevalent neurological disorder, which causes muscle weakness and fatigue. The disorder is caused by an autoimmune condition in which antibodies destroy the communication between nerves and muscle, resulting in weakness of the nerve signal and muscle tiredness.
The myasthenia gravis treatment market is segmented into drug class, age group, and distribution channel. On the basis of drug class, the market is classified into monoclonal antibodies, intravenous immunoglobulin and others. By age group, the market is divided into below 55 years and above 55 years. Depending on distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers.
The major factor driving the growth of the China myasthenia gravis treatment market is surge in the prevalence of myasthenia gravis disorder. According to The World Health Organization (WHO) data, the frequency of myasthenia gravis globally is estimated to be about 0.5 to 20 per 100,000 populaces. Furthermore, increase in number of partnerships between public–private sectors and rise in awareness regarding symptoms and treatments of myasthenia gravis are augmented the growth of the China myasthenia gravis treatment market.
In addition, upsurge in government initiatives to promote awareness about early diagnosis and treatment is anticipated to prompt the market growth. For instance, in January 2019, The European Federation of Neurological Associations (EFNA) introduced a public information campaign to spread awareness regarding myasthenia gravis called ”Your MG is in Your Hands.”
However, certain restraints such as high cost associated with the medical diagnosis and the treatment of this prevalent neurological disorder. In addition, lack of awareness regarding the diagnosis restrains the growth of the China myasthenia gravis treatment market.
Conversely, rise in R&D activities regarding advanced myasthenia gravis treatment tools and medicines, such as botulinum toxic substance, is offering several opportunities for the growth of the market. Furthermore, the financial growth of the developing countries, which at some point results in improved healthcare facilities and availability of the treatment options for myasthenia gravis is anticipated to provide remunerative opportunities for the market growth.
The Porter’s five forces analysis is a model, which analyzes the competitive scenario of the industry and role of each stakeholder. The five forces include the bargaining power of buyers, the bargaining power of suppliers, the threat of new entrants, the threat of substitutes, and the competition among competitive rivalry.
The threat of new entrants is high due to high investment to enter the market and R&D activities. In addition, existing players have a greater one-upmanship due to existing and well-known manufacturing and distribution channels. The threat of substitutes is high due to availability of wide range of medicines and treatments that include monoclonal antibody-based treatment in the market.
The bargaining power of buyers is low due to the presence of well-known medicines and reliable treatments available in the market. The bargaining power of suppliers is moderate due to few suppliers present in the market and consumers need to rely on them. The intensity of competitive rivalry is high due to the few popular players existing in the market and the multitude of medicines provided throughout the world.
The future of the China myasthenia gravis treatment market is anticipated to experience with new developments and technical innovations, more R&D activities, and collaborations to introduce enhanced treatment drugs and devices. The advancement of targeted immunosuppressant such as Alemtuzumab, are set to increase the market growth. In addition, rapid development of cutting-edge and better myasthenia gravis treatments, such as genetics therapies and biologics therapies are expected to develop a major opportunity for the market growth. Furthermore, several government initiatives in campaigns to promote awareness regarding prevalence of myasthenia gravis and launch of new medicines in the market are anticipated to fuel the growth of the China myasthenia gravis market during the forecast period.
Key players included in the report are Nippon Boehringer Ingelheim, Yifan Pharmaceutical, Novartis, Shenzhen Salubris Pharmaceuticals, Shanghai Hainuo Bio Pharm, Shanghai Sanochemia Pharmaceuticals, Celgene Corporation, Pfizer, Gilead Sciences, Bayer AG
Key Benefits For Stakeholders
- Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
- Analyze the key strategies adopted by major market players in China Myasthenia Gravis Treatment Market.
- Assess and rank the top factors that are expected to affect the growth of China Myasthenia Gravis Treatment Market.
- Top Player positioning provides a clear understanding of the present position of market players.
- Detailed analysis of the China Myasthenia Gravis Treatment Market segmentation assists to determine the prevailing market opportunities.
- Identify key investment pockets for various offerings in the market.
China Myasthenia Gravis Treatment Market Report Highlights
| Aspects | Details |
 Forecast period | 2022 - 2032 |
 Report Pages | 79 |
 By Age group |
|
 By Drug class |
|
 By Distribution channel |
|
 Key Market Players | Shanghai Hainuo Bio Pharm, Yifan Pharmaceutical, Bayer AG, Novartis, Gilead Sciences, Pfizer, Celgene Corporation, Nippon Boehringer Ingelheim, Shenzhen Salubris Pharmaceuticals, Shanghai Sanochemia Pharmaceuticals |
The China Myasthenia Gravis Treatment Market is estimated to reach $216.5 million by 2032
Company 1, Company 2, Company 3, Company 4, Company 5, Company 6, Company 7, Company 8, Company 9, Company 10 are the leading players in China Myasthenia Gravis Treatment Market
1. Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
2. Analyze the key strategies adopted by major market players in china myasthenia gravis treatment market.
3. Assess and rank the top factors that are expected to affect the growth of china myasthenia gravis treatment market.
4. Top Player positioning provides a clear understanding of the present position of market players.
5. Detailed analysis of the china myasthenia gravis treatment market segmentation assists to determine the prevailing market opportunities.
6. Identify key investment pockets for various offerings in the market.
China Myasthenia Gravis Treatment Market is classified as by age group, by drug class, by distribution channel
Loading Table Of Content...
Loading Research Methodology...
